Introduction
============

Lapatinib is an oral administration drug for the therapy of metastatic breast cancer (MBC) as a tyrosine kinase inhibitor (TKI) of the epidermal growth factor receptor ([@B29]). The combination of lapatinib and refametinib improves the symptoms of the patients with HER2-positive breast cancer. Lapatinib is effective in treating HER2-positive MBC, but it can cause serious side effects, particularly diarrhea ([@B9]; [@B10]) and skin rash ([@B35]; [@B45]). Capecitabine is another oral drug used in the therapy of breast cancer. The antitumor activity of capecitabine has been widely proved in the salvage therapy of breast cancer ([@B28]) and early breast cancer (EBC). However, capecitabine may cause hand-foot syndrome ([@B38]; [@B41]), stomatitis ([@B34]), and diarrhea ([@B10]).

The combination of capecitabine and an anthracycline-taxane based regimen may be effective and well-tolerated EBC patients, especially for triple negative breast cancer (TNBC) ([@B54]). HER2-positive breast cancer occupies about 20--25% of cases of breast cancer. Trastuzumab is usually considered in the first-line treatment. However, due to cardiotoxicity and increasing resistance associated with trastuzumab, it is highly demanded to explore an effective method for the therapy of breast cancer. There has been increasing interest in treating HER2-positive breast cancer by combining lapatinib and capecitabine. The results suggest that the combination of lapatinib plus capecitabine can improve progression-free survival and overall survival in patients with HER2-positive breast cancer that cannot be controlled by trastuzumab ([@B32]).

Diarrhea will be a main side effect since both lapatinib and capecitabine can cause diarrhea. Moderate to severe diarrhea (an increase of four to six stools over baseline daily) was reported in 20% of patients' in the pivotal trial ([@B14]). Diarrhea can result in dose reduction, delays, poor life quality, high cost for health care, and even life threatening complications sometimes ([@B33]).

Lapatinib and capecitabine therapy can induce mucosal barrier injury ([@B1]), which will result in bacterial infection ([@B5]) and inflammatory responses ([@B6]). All these results will contribute to the diarrhea occurrence. To reduce the side effects, natural products may be a potential option with limited side effects. *Fructus mume (F. mume)*, has long been proved to have anti-bacterial ([@B26]) and anti-inflammatory properties by reducing the levels of proinflammatory cytokines, angiotensin II (Ang II), the receptor for advanced glycation end-products (RAGE), and the mitogen-activated protein kinases (MAPKs) ([@B23]). *F. mume* has long been used in Asian countries to treat chronic diarrhea via its anti-inflammatory activities ([@B23]). An earlier study showed that *F. mume* could alleviate gastrointestinal diseases by down-regulating Th1-polarized immune response and opsonic effect of intestinal commensal bacteria ([@B30]). However, the effects of *F. mume* on human diarrhea are seldom reported. *F. mume* may be effective to treat diarrhea in breast cancer patients receiving the combination therapy of lapatinib and capecitabine, and related work was explored here.

Materials and Methods {#s1}
=====================

Preparation of *F. mume* Extracts
---------------------------------

*Fructus mume* was purchased from Chengdu Dujiangyan Chunsheng Chinese Medicine Drinks Co., Ltd. (Chengdu, China). The species was identified by Professor Bo Liu from Changchun University of Chinese Medicine (Changchun, China). *F. mume* was dried and extracted in 75% ethanol in a shake incubator (Beijing JinMei Entrepreneur Import & Export Co., Ltd., Beijing, China) overnight at room temperature and filtrated with Whatman Quantitative Filter Paper. The extracts of *F. mume* (EFM) were concentrated by using a rotary vacuum evaporator from Kelong Company (Beijing, China).

HPLC Analysis
-------------

The following chromatographic condition was used: XBridge TMC18 column (4.6 mm × 250 mm, 5 μm); injection volume, 10 μl; detection wavelength, 210, 284, and 327 nm; mobile phase, (A) 0.5% NH~4~H~2~PO~3~ solution (phosphoric acid pH 3.0) -- (B) acetonitrile gradient solution, 0--10 min, 95--80% A; 10--15 min, 80--70% A; 15--16 min 70--95% A; and 16--21 min, 95% A, 1 ml/min. Mixed solution of citric acid, 5-HMF, and chlorogenic acid standards (purchased from Sigma) was placed in a 5 mL flask, dissolved and fixed with 20% methanol. A series of control solution was made as the concentrations of 16,200.00, 6,400, and 2,400 mg/l. EFM was dried at low temperature and weighed 0.20 g, and placed in a 250-ml round-bottom flask. The solution was filtered by a 0.22 μm membrane, and diluted into 1 ml by adding 20% methanol.

Ten-microliters standard and sample solution was taken and analyzed according to above chromatographic condition. The detection wavelength was given as follows: citric acid (210 nm), 5-HMF (284 nm), and chlorogenic acid (327 nm). The mixed standards were sequentially diluted to obtain a series of standard solution: citric acid, 8,100.00, 4,050.00, 2,205.00, 1,012.50, 506.30, 253.10, 126.60, and 63.30 mg/l; 5-HMF, 32.00, 16.00, 8.00, 4.00, 2.00, 1.00, and 0. 50 mg/l; and chlorogenic acid, 12.00, 6.00, 3.00, 1.50, 0.75, 0.38, and 0.19 mg/l. The peak area integral value (*Y*) was designed as the ordinate, and the corresponding standard concentration was designed as abscissa (*X*). Linear regression equation was made finally.

Analysis for the Ingredients of EFM From Different Batches
----------------------------------------------------------

Nine batches of EFM powder (batch number 160903452) were prepared in accordance with the above method and analyzed by using above chromatographic condition. Ten-microliters samples were injected and peak areas of three components were measured. The contents of citric acid, 5-HMF, and chlorogenic acid were calculated.

Patients
--------

Before the experiments, all procedures were approved by the research ethical committee from Jilin University (Changchun, China). Meanwhile, written informed consent was obtained from the participants of this study. Clinical characteristics were analyzed, including demographic information, age, BMI (body mass index), and life style so on. In the present study, all patients previously received capecitabine (1.5 g/m^2^ daily every 14 days for one through 10 of a 3-week cycle) and oral lapatinib 1 g daily.

Inclusion Criteria
------------------

The following inclusion criteria were used: occurrence of diarrhea was evaluated by asking during one cycle of combination therapy of lapatinib and capecitabine (at least 21 days), and all patients had more than one risk for ≥ grade 2 diarrhea (Increase of 4--6 stools daily over baseline.) because of the combination therapy of lapatinib and capecitabine; All patients were with advanced MBC.

Exclusion Criteria
------------------

The following criteria was used: the patients suffered from heart \[determined by cardiovascular questionnaire and electrocardiogram (ECG)\], stomach (determined by stomach questionnaire and endoscopy), liver (determined by liver disease questionnaire and salt activity \>50 U/L) and gallbladder (diagnosed by ultrasonic or X-ray techniques), pancreas (diagnosed by duodenoscopy) and kidneys (determined by ultrasound) diseases, and all diseases were determined by responding experts; The following methods were used to evaluate the organs dysfunction. A "threshold" serum creatinine value of 130 μmol/L serum creatinine was used to evaluate kidney dysfunction in women ([@B2]). Threshold of ALT and AST for the diagnosis of liver disease was 19.0 IU/L ([@B37]; [@B48]). The threshold for GGT was 165 U/L for the evaluation of liver function ([@B15]). The threshold for bilirubin toxicity was defined as 20 mg/dL for evaluation kidney function ([@B49]). The threshold for lipase was 1000 U/L for the evaluation of pancreas function ([@B11]).

The patients had colonoscopy intestinal or esophageal stricture, gastrointestinal cancer and other gastrointestinal organic diseases; the patients were gestational or lactating women; the patients suffered from nervous system or mental illness, understanding obstacles, who cannot be communicated; the patients had past history of traditional Chinese medicine allergy. The patients took the treatment of this disease or other drugs affecting gastrointestinal function. The patients with stomas were excluded from the present study.

Patients Grouping
-----------------

The random numbers were generated by a computer combining with clinical variables According to the randomized controlled design method, all the patients were divided into treatment group (EG, the patients received 100 mg EFM daily) and control group (the patients received placebo daily) according to the patient's selection time and random numbers. The chemotherapy was still continued during the whole present experiment. All patients from two groups have light or no work to avoid emotional stress or over exertion. Work has been reported to be associated with breast cancer progression ([@B33]) and diarrhea ([@B47]). 'Light' work was defined as flexed postures, walking and repeated movements, which are involved with the upper limb and light weights ([@B1]). All patients received high protein, low fat and high fiber diet, and limited spicy irritating or greasy food. All the patients received the therapy for 6 weeks. After the therapy, further 4-week follow-up was performed to explore the long-term effects of EFM on diarrhea. Meanwhile, clinical symptoms were measured after 6-week therapy and further 4-week follow-up.

Hematoxylin and Eosin (H&E) Stain
---------------------------------

Five-milligram breast cancer specimens were obtained by needle biopsy. All manipulations of tissue isolation were performed in a biohazard safety laboratory (P3). The isolated specimens were immediately fixed in 10% formalin solution and embedded in paraffin. The embedded paraffin blocks were cut to a thickness of 4-μm section. H&E stain was performed according to an earlier report ([@B42]).

Assessment of Diarrhea and Gastrointestinal Symptoms
----------------------------------------------------

Diarrhea symptom was scored according to an earlier report ([@B17]). Briefly, a semiquantitative method to measure diarrhea scores. Three fecal volumes (+ \< 200 mL, ++ 200--250 mL, +++ \> 250 mL) and three kinds of fecal consistency \[formed (scores, 1, 2, and 3), semisolid (scores, 3, 6, and 9), liquid (scores, 5, 15, and 15)\]. Daily scores were calculated by summing the scores of all stools during a day. Gastrointestinal symptoms were measured according to abdominal Seven-point Likert scale (abdominal pain, bloating, straining, mucus, incomplete evacuation, urgency, wind, hard stool, loose stool, frequency of motions, and nausea) ([@B16]). Scores were recorded by the same corresponding experts during the while experiment. The study was continued for a maximum of 21 days for each time.

Assessment of Quality of Life
-----------------------------

Overall quality of life was measured by SF-36 questionnaire ([@B51]) and Hospital Anxiety and Depression Scale (HADS) score ([@B3]).

Statistical Analysis
--------------------

All statistical analyses were performed by using SPSS 20.0 (SPSS Inc., Chicago, IL, United States). All variables were expressed as mean ± standard deviation (SD). The relationship between clinical characters and diarrhea incidence was analyzed by using univariate and logistic regression. The significant variables (more than 10%) were included as possible indicators. A multivariate analysis was performed by using all the predictors who came out to be significant in the univariate analysis. Patient/treatment characteristics were compared to verify how well the patients were randomized. Chi squared test or student's test was used to compare the treatment efficacy groups among CG and EG. Univariate analysis was performed to explore potential predictor factors associated with the diarrhea. The statistical differences were significant if *P* \< 0.05.

Results
=======

Main Ingredients of EFM
-----------------------

The HPLC analysis showed that there were three components in EFM, including citric acid, 5-HMF, and chlorogenic acid (**Figure [1](#F1){ref-type="fig"}**). **Table [1](#T1){ref-type="table"}** showed linear relationships of major components of EFM during HPLC analysis. Under the experimental condition, the theoretical area for the absorption peak of the chromatogram of the test sample and each standard was not less than 3,000, and the corresponding chromatographic peak resolution was \>1.5.

![HPLC chromatograms of Extracts of *Fructus mume* (EFM) sample and standards. (1) Citric acid; (2) 5-HMF; (3) chlorogenic acid; **(A)** standard. **(B)** Sample detection at 210 nm. **(C)** Sample detection at 280 nm. **(D)** Sample detection at 327 nm.](fphar-09-00516-g001){#F1}

###### 

Linear relationships of major components of EFM.

  Main components    Regression equation     *R*      Linear range        Measure limitation, mg/l   Quantitative limitation, mg/l
  ------------------ ----------------------- -------- ------------------- -------------------------- -------------------------------
  Citric acid        *Y* = 681.4X+30,313     0.9999   63.30 \~ 8,100.00   0.120                      0.401
  5-HMF              *Y* = 117,290X-72,086   0.9999   0.51 \~ 32.00       0.021                      0.070
  Chlorogenic acid   *Y* = 48,662-1300.4     0.9998   0.19 \~ 12.00       0.046                      0.092

The Contents of the Ingredients of EFM Were Stable at Different Batches
-----------------------------------------------------------------------

According to the above HPLC condition, the ingredients of EFM were measured nine times. The RSDs of the peak areas of the components, the peak areas of the obtained citric acid, 5-HMF, and the chlorogenic acid were 1.6, 2.1, and 1.5%, respectively. It indicated that the contents of the ingredients of EFM were stable as **Table [2](#T2){ref-type="table"}** showed. Thus, EFM from different batches would not affect subsequent therapeutic results.

###### 

HPLC analysis of EFM at different batches.

  Ingredients        Total weight/g   Ingredient weight/mg   Addition/mg   Measurement/mg   Recovery/%   Mean value/%   RSD/%
  ------------------ ---------------- ---------------------- ------------- ---------------- ------------ -------------- --------
  Citric acid        0.200            63.389                 50.708        114.092          99.308       99.952         1.632
                     0.200            63.448                 50.647        113.202          97.231                      
                     0.200            63.310                 50.734        113.623          98.902                      
                     0.200            63.426                 63.407        125.813          98.415                      
                     0.200            63.402                 63.376        125.770          98.170                      
                     0.200            63.316                 63.369        126.897          100.106                     
                     0.200            63.362                 76.083        139.527          99.947                      
                     0.200            63.369                 76.098        139.352          99.879                      
                     0.200            63.383                 76.115        140.162          100.775                     
  5-HMF              0.200            0.367                  0.264         0.607            98.702       99.136         1.5372
                     0.200            0.324                  0.231         0.696            100.921                     
                     0.200            0.321                  0.220         0.674            100.270                     
                     0.200            0.389                  0.336         0.767            98.203                      
                     0.200            0.343                  0.345         0.744            97.159                      
                     0.200            0.383                  0.337         0.786            100.491                     
                     0.200            0.358                  0.401         0.808            98.664                      
                     0.200            0.348                  0.409         0.840            99.504                      
                     0.200            0.329                  0.440         0.851            97.825                      
  Chlorogenic acid   0.200            0.364                  0.255         0.580            97.298       99.375         1.124
                     0.200            0.364                  0.238         0.579            100.926                     
                     0.200            0.299                  0.276         0.628            98.587                      
                     0.200            0.281                  0.316         0.706            98.625                      
                     0.200            0.350                  0.322         0.697            98.856                      
                     0.200            0.332                  0.318         0.722            100.187                     
                     0.200            0.343                  0.365         0.758            99.690                      
                     0.200            0.271                  0.383         0.780            99.294                      
                     0.200            0.353                  0.417         0.804            100.396                     

Clinical Characteristic
-----------------------

**Table [3](#T3){ref-type="table"}** showed the clinical characteristics of patients in both groups. Patients who received the combination therapy of lapatinib and capecitabine had a median age of 51 years, and over 90% had a good result. The combination therapy of lapatinib and capecitabine were delivered over a 4-month ere delivered over a 4-month period, and 208 patients had diarrhea episodes. Approximately, 23 and 18% of patients began to receive the therapy in spring and summer in EG and CG, respectively. With respect to the primary endpoint, 208 patients had ≥ grade 2 diarrhea episodes. The statistical difference for the numbers for light work was insignificant between two groups. Diet was controlled throughout the experiment period to match habitual intake according to **Table [3](#T3){ref-type="table"}**.

###### 

Characteristics of patients and treatment received.

  Characteristic                                         EG (*n* = 104)                             CG (*n* = 104)                             *T* value and χ^2^   *P*-value
  ------------------------------------------------------ ------------------------------------------ ------------------------------------------ -------------------- -----------
  Age, year (range)                                      51 (25--79)                                50 (28--78)                                1.578                0.139^a^
  BMI, kg/m^2^                                           23.4 ± 3.7                                 23.8 ± 4.2                                 0.287                0.453^a^
  Smoking, *n* (%)                                       31                                         35                                         0.355                0.551^b^
  Drinking, *n* (%)                                      28                                         24                                         0.410                0.522^b^
  Light work, *n* (%)                                    78                                         83                                         0.687                0.407
  **ECOG performance status**                                                                                                                                       
  0                                                      62                                         60                                         0.137                0.933^b^
  1                                                      37                                         38                                                              
  Missing                                                5                                          6                                                               
  Mean baseline Hb \[g/dL\] (SD)                         12.4 ± 1.7                                 13.7 ± 1.9                                 -2.449               0.070^a^
  Mean baseline WBC \[×10^9^ cells/l\]                   5.9 ± 2.3                                  5.6 ± 2.0                                  1.264                0.274^a^
  Mean baseline platelets \[×10^9^cells/l\]              243 ± 80                                   235 ± 86                                   1.568                0.164^a^
  Median number of metastatic sites                      4 ± 3                                      4 ± 3                                      0.316                0.767^b^
  Surgical treatment                                                                                                                           0.497                0.780^b^
  Lumpectomy, *n* (%)                                    41                                         46                                                              
  MRM, *n* (%)                                           62                                         57                                                              
  Both lumpectomy and MRM, *n* (%)                       1                                          1                                                               
  Radiation                                                                                                                                    0.079                0.961^b^
  Left sided, *n* (%)                                    57                                         59                                                              
  Right sided, *n* (%)                                   46                                         44                                                              
  Bilateral, *n* (%)                                     1                                          1                                                               
  **Metastatic sites**                                                                                                                                              
  Liver                                                  54                                         52                                         0.108                0.998^b^
  Bone                                                   46                                         45                                                              
  Lung                                                   44                                         46                                                              
  Skin                                                   19                                         18                                                              
  Brain                                                  4                                          4                                                               
  Total number of cycles delivered                       1,321                                      1,302                                                           
  Median number of cycles                                18 ± 15                                    18 ± 15                                    0.244                0.451^a^
  Grade 1 diarrhea in the prior cycle                    104 events                                 104 events                                                      
  Concomitant 5HT3 antiemetics                           In 15 cycles                               In 15 cycles                                                    
  **Season treatment was started**                                                                                                                                  
  Spring                                                 24                                         26                                         0.048                0.997^b^
  Summer                                                 18                                         17                                                              
  Fall                                                   30                                         31                                                              
  Winter                                                 32                                         32                                                              
  Development of grade ≥2 diarrhea                       59 events at median of six, 21-day cycle   56 events at median of six, 21-day cycle   0.175                0.675^b^
  **Food categories (g/day)**                                                                                                                                       
  Starchy foods (breads, cookies, potato, rice)          102.4 ± 15.7                               96.8 ± 13.4                                0.764                0.249
  Legumes (chick peas, beans, peas, lentils)             28.4 ± 5.9                                 29.1 ± 6.3                                 0.453                0.518
  Vegetables (pumpkin, chayote, tomato, carrot)          358.9 ± 124.7                              309.5 ± 118.4                              0.795                0.127
  Meat, poultry, fish and eggs                           89.7 ± 40.3                                98.5 ± 36.2                                0.681                0.426
  Fruits                                                 146.3 ± 52.4                               156.1 ± 61.3                               0.328                0.593
  Dairy products (ml)                                    150.0 ± 50.0                               150.0 ± 50.0                               0.148                0.867
  Sweet foods (sweet guava, ice cream, dulce de leche)   78.5 ± 45.2                                80.1 ± 41.6                                0.115                0.859
  Spicy foods (ketchup, pepper)                          15.4 ± 6.8                                 14.9 ± 7.6                                 0.147                0.682

ECOG, Eastern Cooperative Oncology Group;

a

T-test and

b

Chi Square

.

Breast Cancer Types
-------------------

Breast cancer is divided into three types according to the tumor structure and morphology of the myoepithelial. Leaflet type (**Figures [2A,B](#F2){ref-type="fig"}**): this type was more common, and the tumors had complete or incomplete collagen fiber capsule, the fiber capsule extended to the tumor, and the tumor tissues were divided into nodular and lobular. Hyperplasia of myogenic epithelial cells was solid, nested arranged, and the cytoplasm was bright or acidophilic, and some had around plasmacytoid squeezing the gland cavity. The majority of tumor centers were transparent, and some tumors were calcified with large central infarction. Gland type (**Figures [2C,D](#F2){ref-type="fig"}**): most of the tumor borders were unclear and characterized by different sizes of the main gland and myoepithelial cells. Glandular epithelial cells were gathered around the ductal hyperplasia, like sclerosing papilloma, tubular and gland tubular adenoma. The duct could be occluded when myoepithelial hyperplasia. Fibroblast type (**Figures [2E,F](#F2){ref-type="fig"}**): Fibroblast epithelial cells were rich with eosinophilic granules, and myoepithelial cells formed bundle structures. Proliferative cell mass was oppression lumen. The epithelial cells of the gland epithelium were cubic or flat, with a round or oval shape. The cytoplasm was abundant, eosinophilic and common apocrine mucosal secretions. In some areas, fibroids were confused due to the lack of glandular epithelium.

![Breast cancer types. **(A)** (×100) and **(B)** (×400), leaflet type. **(C)** (×100) and **(D)** (×400), gland type. **(E)** (×100) and **(F)** (×400), Fibroblast type.](fphar-09-00516-g002){#F2}

The Risk Factors of Diarrhea Events
-----------------------------------

Univariate analysis of potential predictor factors, the risk factors associated with ≥ grade II diarrhea were age, bone and skin metastases, treatment in spring, creatinine and albumin. Grade one diarrhea is also an important risk factor for diarrhea developing into grade II. A negative relation between risk and amount of medical cycles were found. The results showed that diarrhea incidences were highest in the earlier cycle and then decreased by 13% in one more cycle (**Table [4](#T4){ref-type="table"}**). Using all the predictors who came out to be significant in the univariate analysis, the following risk factors of diarrhea were analyzed by using a multivariate regression model: each additional cycle of two drugs, skin metastases, grade I diarrhea in prior cycle, therapy started in the spring, and brain metastases. The analysis showed that skin metastases, grade I diarrhea in prior cycle, therapy started in the spring, and brain metastases, were found to be significantly associated with IA development (**Table [5](#T5){ref-type="table"}**).

###### 

Predictive factors for diarrhea derived from the database.

  Variable                                     Odds ratio   95% CI         Impact relative risk
  -------------------------------------------- ------------ -------------- -------------------------
  Each additional cycle                        0.86         0.83--0.98     ↓by 13% per cycle
  Skin metastases                              0.26         0.15--0.78     ↓by 73%
  Grade I diarrhea in prior cycle              2.6          (0.91--4.7)    ↑twofold
  Therapy started in the spring                2.3          (1.1--4.2)     ↑twofold
  Planned dose of capecitabine/cycle (grams)   1.22         (0.91--1.24)   ↑by 3.7% with each gram
  Brain metastases                             6.4          (0.93--38.2)   ↑fivefold

###### 

Multivariate model analysis of the risks associated with diarrhea incidences.

  Characteristics                   *P*-value   Odd ratios   95% CI
  --------------------------------- ----------- ------------ ------------
  Each additional cycle             0.12        1.14         0.64--2.52
  Skin metastases                   0.04        0.65         0.17--1.69
  Grade I diarrhea in prior cycle   0.04        2.38         0.56--7.34
  Therapy started in the spring     0.04        2.61         1.07--4.35
  Brain metastases                  0.02        3.28         1.23--7.68

EFM Improved Diarrhea and Gastrointestinal Symptoms
---------------------------------------------------

The average scores of the diarrhea symptom before EFM treatment were 12.97 ± 6.62 and 13.11 ± 7.53 in EG and CG groups (**Figure [3A](#F3){ref-type="fig"}**, *P* \> 0.05), respectively. After 6-week therapy, the average scores of the diarrhea symptom before EFM treatment were 8.47 ± 4.62 and 14.29 ± 8.15 in EG and CG groups, respectively. The reduction in diarrhea symptoms was statistically significant in EG group when compared with CG group (**Figure [3B](#F3){ref-type="fig"}**, *P* \< 0.001). After further 4-week follow-up, the average scores of the diarrhea symptom before EFM treatment were 9.25 ± 4.63 and 13.01 ± 6.24 in EG and CG groups, respectively. The reduction in diarrhea symptoms was still statistically significant (**Figure [3C](#F3){ref-type="fig"}**, *P* \< 0.001). Similarly, the statistical difference for gastrointestinal symptoms was insignificant between EG and CG groups (**Figure [3D](#F3){ref-type="fig"}**, *P* \> 0.05). After 6-week therapy and 4- week follow-up, the reduction in gastrointestinal symptoms was statistically significant in EG group when compared with CG group (**Figure [3D](#F3){ref-type="fig"}**, *P* \< 0.001).

![Therapeutic effects of Extracts of *Fructus mume* (EFM) on breast cancer patients with diarrhea. **(A)** diarrhea scores before therapy. **(B)** Diarrhea scores after 6-week therapy. **(C)** Diarrhea scores after 4-week follow-up. **(D)** The effects of EFM on gastrointestinal symptoms. **(E)** The effects of EFM on SF-36 scores. **(F)** The effects of EFM on HADS scores. EG, the patients received EFM treatment. CG, the patients received placebo treatment. *n* = 104 for each group.](fphar-09-00516-g003){#F3}

EFM Improved Quality of Life
----------------------------

The statistical difference for quality of life was insignificant between EG and CG groups before EFM treatment (**Figures [3E,F](#F3){ref-type="fig"}**, *P* \> 0.05). After 6-week therapy and 4-week follow-up, the improvement of quality of life was statistically significant in EG group when compared with CG group (**Figures [3E,F](#F3){ref-type="fig"}**, *P* \< 0.001).

Discussion
==========

Diarrhea is a common side effect for the agents targeting MBC patients. The present findings demonstrated that EFM improved, diarrhea and gastrointestinal symptoms, and life quality in HER-2 positive breast cancer patients receiving the combination therapy of lapatinib and capecitabine (**Figure [3](#F3){ref-type="fig"}**). The main method in the treatment of chronic diarrhea is to use medicine to regulate gastrointestinal motility ([@B43]; [@B21]), intestinal flora ([@B39]; [@B46]) and protect intestinal mucosal vaccine ([@B27]; [@B53]). However, most medicine causes unwanted adverse side effects. For example, There is increasing evidence to prove that rifaximin is an effective chemoprophylactic drug against travelers' diarrhea, especially in the subjects who have high risk of severe complications caused by acute infectious diarrhea ([@B36]) and inhibited most anaerobic bacteria ([@B13]), whereas the patients may develop neutropenia after the administration of rifaximin ([@B19]). Tricyclic antidepressant amitriptyline has good efficacy in irritable bowel syndrome with diarrhea (IBS-D) ([@B44]), whereas vaccine may cause systemic side effects and its safety and tolerability should be carefully considered for its clinical application ([@B22]).

Extracts of *F. mume* has been widely accepted drugs for the treatment of various diarrhea with its anti-oxidant and anti-inflammatory properties ([@B24]), which have repair and defense capabilities for the gastrointestinal tract. Diarrhea can be caused by various etiologies, such as intestinal secretion, absorption of water and destroyed electrolyte, leading to loss of gastrointestinal capacity and osmotic pressure. Therefore, to maintain intestinal cell motility and electrolyte balance, repair and improve the mucosal defense function of the attack factor is an important method in the treatment of diarrhea. Fortunately, EFM have such functions to regulate gastrointestinal motility ([@B50]) and intestinal secretion ([@B30]) so on.

Citric acid, 5-HMF, and chlorogenic acid were the main ingredients of EFM. Citric acid has been reported to inhibit the all enveloped and non-enveloped viruses that can cause diarrhea ([@B20]). 5-HMF also has antioxidant, anti- diarrhea, antiviral and antibacterial effects ([@B25]). Chlorogenic acid is an antioxidant polyphenol in fruits and vegetables. Chlorogenic acid can prevent intestinal inflammatory conditions ([@B40]). All these characters of three ingredients may contribute to the protective role of EFM in preventing diarrhea risk.

Diarrhea will contribute to gastrointestinal illness and the effects of EFM on gastrointestinal symptoms were also explored by using seven-point Likert scale. The results suggest the ingredients of EFM may contribute to more desirable gastrointestinal milieu. Patients with diarrhea often have psychiatric comorbidities ([@B18]) and alterations in the intestinal microbiota have been regarded to be associated with depression ([@B31]). The present study showed that EFM may have anti-depression properties by reducing HADS scores. Diarrhea is also associated with significant impairment in health-related quality of life ([@B8]). EFM treatment could improve life quality of MBC patients by increasing SF-36 scores.

The present univariate and multivariate analyses showed that skin metastases, grade I diarrhea in prior cycle, therapy started in the spring, and brain metastases were associated with diarrhea severity. All these factors were all consistent with previous reports. Lapatinib treatment may induce diarrhea and skin side effects ([@B4]), whereas skin lesions also can increase diarrhea risks ([@B12]). Diarrhea grade 1 does not require treatment but it can induce the risk of diarrhea grade 2 or a higher grade ([@B7]). Spring is an important season to control diarrhea ([@B52]). Brain-gut function plays an important role in the diarrhea risk ([@B55]) whereas brain metastases will affect the interaction between brain and gut.

There were some limitations in the present stud. The present study mainly focused on only diarrhea and most other parameters were not measured, such as intestinal secretion, absorption of water and destroyed electrolyte. We did not explore the molecular mechanisms for the functional role of EFM in the treatment of diarrhea cause by the combination of lapatinib and capecitabine. Thus, the exact mechanism for the effects of EFM on the diarrhea remains unclear. There are also other safety aspects, including dose intensity, rash, mucositis and drug interactions that were not addressed in the present manuscript, but would be important to consider in the future work. There should be a dose difference among these patients and the related results would be critical to understand functional role of EFM. Therefore, further work is highly demanded to address these issues.

In sum, the results of this study suggest that EFM can significantly improve diarrhea and gastrointestinal symptoms, and the life quality of MBC patients with the diarrhea caused by the combination therapy of lapatinib and capecitabine. EFM may be a potential choice for treating the diarrhea caused by the combination therapy of lapatinib and capecitabine in breast cancer patients.

Author Contributions
====================

HX designed the experiments. LZ collected all data. JM analyzed all data. ZL and CS performed all the experiments and analyzed the data. YL wrote the paper.

Conflict of Interest Statement
==============================

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

We are very grateful to the two reviewers for their critical and strategical comments, which have significantly improved the quality of the present paper.

[^1]: Edited by: Mingliang Cheng, Guiyang Medical University, China

[^2]: Reviewed by: Michelle Lui, Juravinski Hospital, Canada; Zhiling Yu, Hong Kong Baptist University, Hong Kong

[^3]: This article was submitted to Ethnopharmacology, a section of the journal Frontiers in Pharmacology
